UBS analyst Danielle Antalffy initiated coverage of Procept BioRobotics (PRCT) with a Buy rating and $62 price target The firm’s key onion leader checks provide conviction in the company’s utilization growth in 2026 and 2027. It views the recent selloff in the shares as a buying opportunity. Procept’s focus on driving utilization on its existing installed base, underpenetrated system placement market, and mix-driven margin expansion are underappreciated by the market, the analyst tells investors in a research note.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRCT:
- Promising Growth and Investment Opportunity for PROCEPT BioRobotics: Analyst Buy Rating
- Procept BioRobotics falls -7.0%
- Procept BioRobotics downgraded to Neutral at BofA on slowing utilization
- Procept BioRobotics downgraded to Neutral from Buy at BofA
- Procept BioRobotics price target lowered to $51 from $56 at Morgan Stanley